Compare McKesson Corporation (MCK) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Transocean Ltd — how do they compare? McKesson Corporation trades at $825.67 (market cap $97.35B), while Transocean Ltd trades at $5.19 (market cap $5.56B). The key difference: McKesson Corporation is far larger — about 17.5× Transocean Ltd's market cap, and McKesson Corporation pays a 0.39% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals.
| MCK | RIG | |
|---|---|---|
Market Cap | $97.35B | $5.56B |
Sector | Health | Technology |
52-Week High | $995.69 | $7.58 |
52-Week Low | $659.01 | $2.64 |
Enterprise Value | $101.98B | $10.50B |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Transocean Ltd. (RIG) trades at $5.02, down 2.33% on the day, reflecting a bearish technical trend. The company reported a net loss of $2.92 billion in 2025 despite $3.97 billion in revenue, with a negative net income margin of -66.79%. Recent news highlights a significant $1 billion contract with Equinor and a pending merger with Valaris, aimed at reducing leverage and generating synergies. Analyst consensus is mixed, with a $7.00 price target suggesting potential upside from current levels.
The outlook for RIG hinges on successful execution of its merger and contract backlog conversion to profitability. Opportunities include a strong $7 billion backlog and operational momentum, but risks persist from sustained net losses, high debt, and oil price volatility. Investors should weigh the potential for deleveraging and synergy benefits against ongoing profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
